Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Small Cell Lung Carcinoma 10Carcinoma, Non-Small-Cell Lung 10Carcinoma, Hepatocellular 8Lung Neoplasms 6Colorectal Neoplasms 6Neoplasms 5Prostatic Neoplasms 4Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Solid Tumors 2Small Cell Lung Cancer Extensive Stage 2Sarcoma, Alveolar Soft Part 2Sarcoma 2Ovarian Neoplasms 2Mesothelioma, Malignant 2Melanoma 2Liver Neoplasms 2Extensive Stage Lung Small Cell Carcinoma 2Carcinoma, Renal Cell 2Carcinoma 2Wilms Tumor 1Vulvar Neoplasms 1Vaccinia 1Sarcoma, Clear Cell 1Rhabdomyosarcoma 1Papillary renal cell carcinoma, sporadic 1PIK3CA-Mutated Cancers 1Osteosarcoma 1

Interventions

atezolizumab 2tocilizumab 1spartalizumab 1pembrolizumab 1fludarabine phosphate 1fludarabine 1adagrasib 1Trastuzumab 1Pemetrexed 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1Fluorouracil 1Docetaxel 1Cyclophosphamide 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Solid Tumors × atezolizumab × 30 days × Clear all
NCT04303858 2026-06-02

A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors

Hoffmann-La Roche

Phase 1 Terminated
189 enrolled
Other solid neoplasm

Solid Tumors

NCT04250155 2026-05-26

An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Genentech, Inc.

Phase 1 Active not recruiting
195 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡